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BACKGROUND & AIMS: Pancreatic ductal adenocarci-
noma (PDA) is an aggressive tumor, and patients typically
present with late-stage disease; rates of 5-year survival
after pancreaticoduodenectomy are low. Antibodies
against -enolase (ENO1), a glycolytic enzyme, are de-
ected in more than 60% of patients with PDA, and
NO1-specific T cells inhibit the growth of human pan-
reatic xenograft tumors in mice. We investigated whether
n ENO1 DNA vaccine elicits antitumor immune re-
ponses and prolongs survival of mice that spontaneously
evelop autochthonous, lethal pancreatic carcinomas.
ETHODS: We injected and electroporated a plasmid
ncoding ENO1 (or a control plasmid) into KrasG12D/Cre
(KC) mice and KrasG12D/Trp53R172H/Cre (KPC) mice at 4
eeks of age (when pancreatic intraepithelial lesions are
istologically evident). Antitumor humoral and cellular
esponses were analyzed by histology, immunohistochem-
stry, enzyme-linked immunosorbent assays, flow cytom-
try, and enzyme-linked immunosorbent spot and cyto-
oxicity assays. Survival was analyzed by Kaplan–Meier
nalysis. RESULTS: The ENO1 vaccine induced antibody
nd a cellular response and increased survival times by a
edian of 138 days in KC mice and 42 days in KPC mice
ompared with mice given the control vector. On histo-
ogic analysis, the vaccine appeared to slow tumor pro-
ression. The vaccinated mice had increased serum levels
f anti-ENO1 immunoglobulin G, which bound the sur-
ace of carcinoma cells and induced complement-depen-
ent cytotoxicity. ENO1 vaccination reduced numbers of
yeloid-derived suppressor cells and T-regulatory cells
nd increased T-helper 1 and 17 responses. CONCLU-
IONS: In a genetic model of pancreatic carcinoma,
accination with ENO1 DNA elicits humoral and cel-
ular immune responses against tumors, delays tumor
rogression, and significantly extends survival. This
accination strategy might be developed as a neoadju-
ant therapy for patients with PDA.
eywords: Th17; IFN-; Antitumor Immunity; Immuno-
herapy.Pancreatic ductal adenocarcinoma (PDA) is the fourthleading cause of cancer-related death in Western
ountries. Surgical resection is the only potentially cura-
ive treatment. Unfortunately, because of the late presen-
ation of the disease, only 15% to 20% of patients are
andidates for pancreatectomy. However, the 5-year sur-
ival rate after pancreaticoduodenectomy is only 25% to
0% for node-negative and 10% for node-positive tu-
ors.1,2 Effective diagnostic and therapeutic strategies are
till urgently needed to improve this survival rate. We have
sed SERological Proteome Analysis to identify a dozen
ntigens expressed by PDA and recognized by autoanti-
odies present in the sera of patients with pancreatic
ancer but not in the sera of patients with other tumors,
atients with pancreatitis, or healthy donors.3 One of
hese antigens, -enolase (ENO1), is specifically recog-
nized by more than 60% of patients with PDA.4 ENO1 is
oded by the ENO1 gene, is overexpressed in the cyto-
lasm of PDA cells, and is also present on their mem-
rane.5 In the cytoplasm, ENO1 acts as a glycolytic en-
zyme, whereas on the membrane it acts as a plasminogen
receptor and plays an important role in cell migration.6,7
We have shown that patients with PDA with autoantibod-
ies to ENO1 also present an ENO1-specific T-cell response
that is not observed in patients with no ENO1 autoanti-
bodies. On transfer into immunocompromised mice,
ENO1-specific T cells inhibit the growth of xenotrans-
planted human pancreatic tumors. Despite the ubiqui-
tous presence of ENO1 in all mammalian cells, normal
cells expressing low levels of ENO1 are spared by ENO1-
specific cytotoxic T lymphocytes.5
In this work, we used 2 genetically engineered mice
strains (KrasG12D/Cre mice [KC mice] and KrasG12D/
Trp53R172H/Cre mice [KPC mice]) that develop autochtho-
nous lethal pancreatic carcinomas with different kinet-
Abbreviations used in this paper: BSA, bovine serum albumin; ENO1,
-enolase; IFN, interferon; Ig, immunoglobulin; IL, interleukin; KC,
rasG12D/Cre mice; KPC, KrasG12D/Trp53R172H/Cre mice; mAb, mono-
clonal antibody; MDSC, myeloid-derived suppressor cells; PBS, phos-
phate-buffered saline; PDA, pancreatic ductal adenocarcinoma; rENO1,
recombinant human ENO1; TNF, tumor necrosis factor; Treg cell, T-reg-
ulatory cell.
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May 2013 DNA VACCINATION DELAYS PROGRESSION OF PDA 1099ics8,9 to study the protective effect of a DNA vaccine to
uman ENO1.
Mice were vaccinated with plasmids encoding human
NO1 because it displays more than 95% identity (99%
omology) with the mouse orthologue. Vaccination, start-
ng from 4 weeks of age, when pancreatic intraepithelial
esions are already histologically evident,8 elicits an inte-
grated humoral and cellular immune response to ENO1
that significantly extends survival. Our data also show a
new role of ENO1 in skewing the T-cell response toward
a Th17-type response. ENO1 vaccination may therefore be
a promising neoadjuvant form of PDA management.
Materials and Methods
Mice
Mice carrying single-mutated KrasG12D (C57BL/6;129SvJae
H-2b) or double-mutated (KrasG12D and Trp53R172H) (129SvJae H-2b)
nder the endogenous promoter and flanked by Lox-STOP-Lox
assettes were obtained from Dr David Tuveson (Cancer Re-
earch UK, Cambridge Research Institute, Cambridge, England).
57BL/6 mice expressing Cre recombinase under a specific pan-
reatic transcriptional factor, pancreatic duodenum homeobox 1
Pdx-1), promoter were obtained from Dr Andrew Lowy (Uni-
ersity of San Diego, San Diego, CA). Mice were bred and
aintained under saprophytic and pathogen-free conditions at
he animal facilities of the Molecular Biotechnology Center and
reated in accordance with EU and institutional guidelines. Pan-
reatic cancer–prone KC and KPC mice were generated by cross-
ng single-mutated KrasG12D or double-mutated KrasG12D and
rp53R172H with C57BL/6 mice expressing Cre recombinase.
ice were screened by polymerase chain reaction using tail DNA
mplified by specific primers to the Lox-P cassette flanking Kras
nd wild-type Kras genes, the Lox-P cassette flanking Trp53
utated and wild-type Trp53 and Cre recombinase genes. Poly-
erase chain reaction products were separated on 1.5% agarose
els with GelRed (Biotum by SIC, Rome, Italy) and recorded as
tiff.
DNA Vaccination
KC and KPC mice were vaccinated at 4 weeks of age and
every 3 weeks for a total of 3 rounds of vaccination or every 2
weeks for a total of 4 rounds of vaccination. In the therapeutic
DNA vaccination setting, KC mice were vaccinated at 32 to 36
weeks of age and every 3 weeks for a total of 3 rounds of
vaccination. Injection of 50 g of plasmid in 40 L of sterile
ater with 0.9% NaCl into the femoral muscle of mice anesthetized
ith Zoletil (Rompun) e Xylazina was immediately followed by two
5-millisecond pulses of 375 V/cm applied with a Cliniporator and
inear needle electrodes (IGEA, Carpi, Italy). KC and KPC mice of
he same age were randomly assigned to control and treatment
roups, and all groups were specifically treated concurrently. Mice
ere monitored weekly and left to live unless showing obvious
igns of pain to obtain a Kaplan–Meier survival curve. Parallel mice
ere killed at 4, 24, and 36 weeks of age as indicated to perform
istologic or immunohistochemical analyses.
Human ENO1 complementary DNA was obtained by enzyme
digestion of the plasmid pRC-ENO110 (kindly provided by A.
iallongo, Institute of Biomedicine and Molecular Immunol-
gy, National Council of Research, Palermo, Italy) in HindIII and
baI restriction sites (both from M-Medical, Milan, Italy), fol-
owed by separation by electrophoresis on agarose gel and elu-ion. It was then cloned into pVAX1 (Invitrogen, Milan, Italy),
reviously digested with the same restriction enzymes, by liga-
ion. To propagate and maintain empty and pVAX-ENO1 vec-
tors, the competent recA1, endA Escherichia coli strain (TOP10)
was transformed with the empty pVAX and ligation mixture and
selected on Luria Bertoni plates containing 50 g/mL kanamy-
cin.
Cells
Syngeneic murine DT6606 and K8484 cells were kindly
provided by Dr K. Olive (Li Ka Shing Centre, Cambridge Re-
search Institute, Cancer Research UK, Cambridge, England).
They were obtained from a KrasG12D/Cre and a KrasG12D/
Trp53R172H/Cre pancreatic tumor mass, respectively, and were
aintained in vitro in Dulbecco’s modified Eagle medium/10%
etal bovine serum.
Enzyme-Linked Immunosorbent Assay
Anti-ENO1 immunoglobulin (Ig) G was measured by
enzyme-linked immunosorbent assay by binding to recombinant
human ENO1 (rENO1) (1.5 g/mL in Na2CO3 0.1 mol/L),
produced as previously described.5 Sera collected 2 weeks after 3
ounds of vaccination were diluted 1:500 in phosphate-buffered
aline (PBS) and antibody concentration was calculated by re-
ression analysis using 8 two-fold serial dilutions of 1 g/mL of
72/1.11 monoclonal antibody (mAb) for a standard curve
(kindly provided by P. Migliorini, University of Pisa, Pisa, Italy).
Serum-binding potential. Sera from untreated and
empty or ENO1-vaccinated mice were used to stain DT6606 or
K8484 cells, which were analyzed by flow cytometry after dilution
of 1:50. Briefly, 1  105 cells were washed with PBS/0.2% bovine
erum albumin (BSA)/0.01% NaN3 and incubated with diluted sera
or 1 hour at 4°C. After 2 washes, cells were incubated with an
PC-conjugated anti-mouse antibody (1:200; Biolegend; Prodotti
ianni, Milan, Italy) for 30 minutes on ice. Following washing,
0,000 cells were acquired with a FACSCanto using CellQuest
oftware (both BD Biosciences, Buccinasco, MI, Italy). The antibody
iter is expressed as serum binding potential 103/mL, calculated
as previously described in detail.11
Complement-dependent cytotoxicity. DT6606 or
8484 cells were seeded in a 96-well plate (5  103/well) in
ulbecco’s modified Eagle medium/1% fetal bovine serum over-
ight for adhesion. Cells were washed with warm PBS, incubated
ith sera diluted in PBS (1:50) for 1 hour at 4°C, and washed
gain, followed by incubation with fresh reconstituted rabbit
omplement (Low-Tox rabbit complement; Cedarlane; Euro-
lone, Milan, Italy) diluted 1:25 in PBS for 1 hour at 37°C. Lysis
as evaluated with the CytoTox 96 Non-Radioactive Cytotoxic-
ty Assay (Promega, Milan, Italy). Lysis buffer was added to cells
5 minutes before centrifugation to obtain the maximum release
f lactate dehydrogenase, while cells without serum and com-
lement were used as a measure of spontaneous release of lactate
ehydrogenase. Plates were centrifuged at 250g for 4 minutes
nd 50 L of supernatant was transferred to the enzymatic assay
late and incubated with 50 L of substrate mix for 30 minutes
t room temperature in the dark. Stop solution (50 L) was
added to each well, and absorbance was recorded at 490 nm
with a plate reader. A lactate dehydrogenase positive control
was added in new wells of each plate, and all tests were
performed in triplicate. The percentage of specific lysis was
calculated using the following formula: % Cytotoxicity 
([Experimental  Target Spontaneous]/[Target Maximum 
Target Spontaneous])  100.
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1100 CAPPELLO ET AL GASTROENTEROLOGY Vol. 144, No. 5Interferon Gamma Enzyme-Linked
Immunosorbent Spot Assay
Mouse lymph node and spleen cells were evaluated to
determine the presence of T cells able to secrete interferon
(IFN)- in response to rENO1 or DT6606 cells ex vivo or after 1
eek of in vitro culture in the presence of 10 g/mL of rENO1.
itrocellulose plates (Millipore, Milan, Italy) were coated with
nti–IFN- capture mAb (mIFN- kit; BD Biosciences) overnight
t 4°C. T cells from lymph nodes and spleens ex vivo or recov-
red from a 1-week culture were stimulated with DT6606 cells
1:10 S/E) or rENO1 for 40 hours at 37°C. T cells were seeded
t 3  105 cells/well, and all conditions were performed in
uadruplicate. Plates were then developed as indicated by the
anufacturer using AEC (Sigma-Aldrich, Milan, Italy) substrate,
nd spots were quantified with the microplated reader along
ith a computer-assisted image analysis system (AID; Amplifon,
ilan, Italy). The number of spots was calculated by subtracting
he number of spots in medium only (background) from that in
he presence of stimuli.
Flow Cytometry
Mouse myeloid-derived suppressor cells (MDSCs) were
analyzed by staining whole blood after red cell lysis with 0.83%
NH4Cl/0.1% KHCO3/0.04% EDTA buffer and washing with PBS/
.2% BSA/0.01% NaN3. This was followed, after blocking non-
specific sites, by incubation with the following mAbs from Bio-
legend: anti-CD16/CD32 mAb, anti-CD11b, and anti-Gr1.
Mouse peripheral blood mononuclear cells, isolated by Ficoll
centrifugation, were washed with PBS/0.2% BSA/0.01% NaN3,
stained with CD4 and CD25 mAbs (all from Biolegend), and
subsequently fixed and permeabilized with Fixation and Permea-
bilization Solution (eBioscience; Campoverde, Milan, Italy) for
30 minutes at 4°C. After washing with permeabilization buffer,
cells were incubated for 30 minutes with FoxP3 and RoRt
mAbs (both from eBioscience). Spleen cells (2  106/mL) from
control or ENO1-vaccinated mice were stimulated with phorbol
myristate acetate (50 ng/mL) and ionomycin (2 g/mL) in the
resence of the intracellular protein transport inhibitor brefel-
in A (Sigma-Aldrich) ex vivo or after 1 week of culture in the
resence of rENO1. Cells were harvested 5 hours later, labeled
ith a CD4 mAb, and subsequently fixed with a 2% paraformal-
ehyde solution. Cells were permeabilized using PBS/0.2% BSA/
.5% saponin and subsequently incubated for 30 minutes with
Abs specific for tumor necrosis factor (TNF)-, IFN-, and
nterleukin (IL)-17 (all from BD or Biolegend). All flow cytom-
try data were acquired on a FACSCalibur (BD Biosciences) and
nalyzed using FlowJo (Tree Star from BD Biosciences) or Cell-
uest software (BD Biosciences).
Histology
Pancreas, spleen, liver, and lungs from control and
ENO1-vaccinated mice were sampled at the indicated times, fixed
in formalin, and subsequently paraffin embedded. We quantified
the percentage of transformed ducts compared with normal
ducts on histologic sections from H&E-stained sections of the
pancreas, according to the criteria previously established.8
For immunohistochemical analysis, slides were subjected to
microwaving for 20 minutes in 10 mmol/L of citrate buffer (pH
8.0 for nuclear antigens; pH 6.0 for other antigens). Immuno-
staining was performed using the avidin biotin peroxidase com-
plex method or detected using the Dako Envision Plus Rabbit
Polymer (K4033) and a semiautomated immunostainer (Dako,
Carpinteria, CA, or Ventana Systems, Tucson, AZ). The primaryntibody used was a rat anti-mouse FoxP3 1:50 (eBioscience)
nd a rat anti-mouse CD3 1:100 (Dako). Reactive T lymphocytes
nd T-regulatory (Treg) cells were quantified by measuring the
ercentages of CD3 and FoxP3 cells, respectively, among the
otal mononuclear cells infiltrating the neoplastic pancreatic
lands.
Statistical Analysis
We used an unpaired 2-tailed Student t test for all
comparisons. Kaplan–Meier survival curves were created with
GraphPad software (Prism 5, La Jolla, CA) and evaluated with
both the log-rank Mantel–Cox and the Gehan–Breslow–Wilc-
oxon test.
Results
ENO1 Vaccine Induces Both an Antibody and
a Cellular Response
PDA-prone KC mice were electroporated either
with empty plasmid or human ENO1-encoding plasmid.
The amount of antibodies able to bind rENO1 was eval-
uated at 2 weeks after the last electroporation. Anti-ENO1
antibodies were significantly induced in ENO1-vaccinated
KC mice, but not in those vaccinated with the empty
vector (Figure 1A).
To evaluate the functional role of anti-ENO1 antibod-
ies, we first analyzed the ability of sera from empty- or
ENO1-vaccinated mice to bind the cell surface of murine
PDA cells by flow cytometry by measuring their binding
potential (Figure 1B–D). Despite a weak cell decoration
also being observed with sera from untreated mice, those
from ENO1-vaccinated mice displayed higher serum bind-
ing potential (Figure 1B, D) and a significantly higher
ability to mediate complement-dependent killing of both
murine PDA K8484 and DT6606 cells (Figure 1D, E).
Spleen and lymph node cells from untreated, empty-
vaccinated, and ENO1-vaccinated mice were collected 2
weeks after the final vaccination, and their ability to
secrete IFN- was assessed in an enzyme-linked immu-
nosorbent spot assay, both ex vivo and after 7 days of in
vitro restimulation with the rENO1. Ex vivo splenocytes
from untreated and empty-vaccinated control mice (white
and gray bars) displayed few specific spots when stimulated
with rENO1 (Figure 2B and C). In contrast, ex vivo T cells
from ENO1-vaccinated mice (black bars) displayed a signif-
icantly higher number of IFN-–secreting cells in re-
ponse to rENO1 (Figure 2B), which increased 3-fold after
he in vitro rENO1 restimulation (Figure 2D). When
T6606 cells were used for stimulation, only rENO1-
estimulated T cells from ENO1-vaccinated mice specifi-
ally secreted IFN- (Figure 1E). No IFN-–secreting cells
ppeared when DT6606 cells were preincubated with an
nti–major histocompatibility complex class I antibody.
imilar results were obtained with lymph node cells (data
ot shown).
ENO1 DNA Vaccine Prolongs Mouse
Survival
Because electroporation of human ENO1-encod-ing plasmid induces both cellular and antibody-mediated
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May 2013 DNA VACCINATION DELAYS PROGRESSION OF PDA 1101immune reactions, the therapeutic efficacy of this re-
sponse was evaluated. As shown in Figure 3A and B,
almost all KC mice displayed transformed foci in the
pancreas at the moment of the first electroporation. Their
number increased until the tumor mass reached 85% to
100% of the pancreas, and 50% of mice died around 336
days of age due to the presence of large tumors (Figure
3C). The vaccination with empty vector slightly prolonged
the median of survival by 56 days (P  .9; log-rank
Mantel–Cox test). In ENO1-vaccinated mice, the median
survival was extended by 140 days (50% of mice died
around 474 days; P  .033 vs untreated mice; log-rank
Figure 1. Electroporation of human ENO1-encoding plasmid elicited
antibodies to human and mouse ENO1. (A) Anti-ENO1 IgG was quanti-
fied by enzyme-linked immunosorbent assay in sera from untreated
(white bars) and empty- (gray bars) or ENO1-plasmid (black bars) vacci-
nated mice after 3 rounds of vaccination. Data are represented as
mean  SEM. (B) Serum binding potential evaluated by flow cytometry
with empty- or ENO1-vaccinatedmouse sera collected 2weeks after the
nal vaccination. Values are expressed as mean  103  SEM from
–10 mice. *Values from ENO1-vaccinated mice are significantly differ-
nt from those of empty-vaccinated mice. Representative staining of
urine DT6606 PDA cells with sera from (C) empty- or (D) ENO1-vacci-
ated mice that were individually tested. Open profiles, cells stained with
econdary antibody alone; solid black profiles, cells stained with sera
rom mice vaccinated with empty (left panel) or ENO1 (right panel) plas-
ids. Two representative stainings are shown. (E) Complement-depen-
ent cytotoxicity of K8484 and DT6606 cells with sera from empty- or
NO1-vaccinated mice that were individually tested. The box graphs
nclude single percent of lysis SEM, and the horizontal bars represent
he median for each group of sera. *P  .05 and ***P  .0001 values
rom ENO1-vaccinated mice are significantly different from those of
mpty-vaccinated mice. §§P  .001.Mantel–Cox test) (Figure 3C), which amounts to more Tthan one-third of their life expectancy. Despite the slight
increase induced by the unspecific vaccination and elec-
troporation, the ENO1 vaccine significantly prolonged the
survival by a further 82 days (P  .036 vs empty-vacci-
nated mice; log-rank Mantel–Cox test).
Even the survival of the double-mutated KPC mice, in
which faster tumor progression was evident from their
shorter median survival (203 days compared with 336
days for KC mice), was prolonged by 42 days (20% of life
expectancy; P  .034 vs untreated mice and P  .025 vs
empty-vaccinated mice; log-rank Mantel–Cox test) in
ENO1-vaccinated mice but not in empty-vaccinated mice
(50% of mice died around 160 days; P  .25 vs untreated
mice; log-rank Mantel–Cox test) (Figure 3D).
Because of the small number of available KPC mice,
histologic and immunologic studies were conducted on
KC mice only. Histologic analysis performed at 24 and 36
weeks of age with randomly vaccinated mice (n  5 per
group) confirmed the ability of the ENO1 vaccine, and to
a lesser extent electroporation with the empty plasmid, to
reduce the percentage of transformed ducts compared
with control mice. At 24 weeks, while untreated KC mice
displayed 58% of already transformed pancreatic ducts,
those empty vaccinated or those receiving ENO1 vaccine
displayed only 18% and 25.5%, respectively (Figure 3E). At
36 weeks, ducts were shown to be transformed in 85% of
the pancreas of untreated mice and 56% in those empty
vaccinated compared with only 40% in those ENO1 vacci-
nated (Figure 3F); 2 of these mice displayed an almost
normal pancreas, suggesting a complete recovery.
ENO1 DNA Vaccine Inhibits MDSC and
Treg Cell Expansion and Promotes the
Th17 Response
Because MDSCs and Treg cells have been reported
in KC mice,12 the effect of ENO1 DNA vaccination on
hese cell subsets was investigated. Compared with con-
rol mice at 12 weeks of age, there was a similar percent-
ge of MDSCs (white bars, Figure 4A, left panel) in the
lood of empty-vaccinated mice (gray bars), which signif-
cantly decreased in ENO1-vaccinated mice (black bars),
ith an even more pronounced effect in Treg cells (Figure
A, right panel). The percentages of MDSCs and Treg cells
n ENO1-vaccinated mice then increased to those of con-
rol mice at 52 and 76 weeks (Figure 4A).
Immunohistochemical examination of pancreatic tis-
ues from untreated mice shows a progressive increase of
oxP3 cells in transformed ducts from 3% at 4 weeks of
ge to 13% at 24 weeks and 19% at 36 weeks. Empty
accination did not alter this progress, whereas the ENO1
accine significantly diminished both the 24- and 36-week
ercentages (Figure 4B–F). It will be seen that these 2
ercentages are stable.
Compared with untreated and empty-vaccinated mice,
n ENO1-vaccinated mice the percentage of Treg cells
ecreased in parallel with the increase of the percentage of
ells expressing RoRt, a transcriptional factor related to
h17 cells13 (data not shown). This corresponded to an
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1102 CAPPELLO ET AL GASTROENTEROLOGY Vol. 144, No. 5increased percentage of cells secreting IL-17 and TNF-, 2
signature cytokines of Th17 cells,14 accompanied by an
increase of IFN-–secreting cells in CD4 spleen cells
rom ENO1-vaccinated mice (Figure 5A). After 7 days of in
itro restimulation, the percentage of IL-17–, TNF-–,
IFN-–, and IL-17/TNF-–secreting cells significantly in-
reased even further (Figure 5B). Furthermore, we ana-
yzed by immunohistochemistry the CD3 infiltrate into
eoplastic foci from pancreas collected from untreated
ice and mice vaccinated with empty or ENO1-expressing
lasmids. As shown in Figure 5C–F, the percentage of
D3 on total inflammatory cells in the neoplastic foci was
ignificantly higher in ENO1-vaccinated mice compared
ith that observed in empty-vaccinated or untreated mice.
These results suggest that only the ENO1 vaccination
as able to induce specific Th17 cells in parallel, to di-
inish the frequency of suppressor cells such as MDSCs
nd Treg cells, and, of note, to actively recruit CD3 cells
nto the tumor.
Therapeutic ENO1 DNA Vaccine Significantly
Slows Progression of PDA
To evaluate the effect of the ENO1 vaccine in a
setting closer to that applicable in patients with late
diagnosed or chemoresistant or radioresistant tumors, we
vaccinated mice at 32 to 36 weeks of age. Mice were killed
Figure 2. ENO1 vaccine elicited cellular responses to human and mous
ars), or ENO1 plasmid-vaccinated (black bars) mice were stimulated o
nd D) DT6606 cells (A and B) ex vivo or (C and D) after 7 days of st
anti–major histocompatibility complex class I mAb (D). T cells cultured w
represent the mean number of specific spots subtracted from that of th
experiments is shown, and results are expressed as mean  SEM. n 
mice and §§P  .001, §§§P  .0001 values compared with empty-vacciat 52 weeks of age to evaluate by histologic analysis the cpercentage of transformed ducts compared with the nor-
mal ducts. Empty-vaccinated mice showed approximately
79% of transformed ducts compared with approximately
50% observed in the pancreas of ENO1-vaccinated mice
(Figure 6A). Although the difference in the percent of
transformed ducts was not statistically different, the
mean dimension of the largest tumor is strongly and
significantly less in ENO1-vaccinated mice compared with
that evaluated in empty-vaccinated mice (Figure 6B).
These results suggest that even in a desperate attempt to
tackle PDA when tumors are well established, the ENO1
vaccine seems to have efficacy in delaying tumor progres-
sion.
Discussion
We have previously shown that ENO1, a novel
PDA-associated antigen, could be a promising therapeutic
candidate owing to its ability to induce an integrated
humoral and cellular response.5 The few PDA-associated
antigens (CEA, Kras, MUC1, and gastrin) that have al-
ready been tested in clinical trials have been shown to
have no effect on survival.15 This highlights the challenge
o identify new and more significant immunogenic tar-
ets.
Here we show, for the first time, that a DNA vaccine
O1. Spleen cells from untreated mice (white bars), empty plasmid (gray
enzyme-linked immunosorbent spot plate with (A and C) rENO1 or (B
lation with rENO1. DT6606 cells were either preincubated or not with
medium alone are shown as light gray bars. The numbers in the graph
ackground. All conditions were in quadruplicate. One of 3 independent
r each group. *P  .05, ***P  .0001 values compared with untreated
d mice.e EN
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May 2013 DNA VACCINATION DELAYS PROGRESSION OF PDA 1103specific immune response that prolongs survival in a
mouse model of PDA. Despite ENO1 being widely ex-
pressed, we have previously shown that normal cells,
whose ENO1 levels are lower than those of tumor cells,
Figure 3. ENO1 vaccine significantly prolonged survival of KC and KPC
mice. (A andB) From 4weeks of age, KCmice spontaneously developed
DA that histologically progressed from PanIN to carcinoma in situ. (C
nd D) Kaplan–Meier analysis of survival of untreated and vaccinated
ith empty or human ENO1 coding plasmid (C) KC mice and (D) KPC
ice monitored until their death. Percentage of transformed ducts in KC
ice untreated or vaccinated with empty or ENO1 DNA at 24 (E) and 36
F) weeks. **P  .001 values compared with untreated mice.are spared from antigen-specific killing.5 .In this study, LSL-KrasG12D mice crossed with Pdx-1-Cre
mice (KC mice) were used to obtain the specific expression
of mutated KrasG12D in pancreatic cells. Each tumor
evolves from a background of genomic instability that
gives rise to a polyclonal tumor with physiopathological
features that are similar to those of human PDA.8 Indeed,
igh-resolution assessments of chromosomal content
ave previously indicated that nonreciprocal transloca-
ions were found in most neoplastic cells that were ana-
yzed.16 This and similar models of genetically engineered
mice have been used to address therapeutic issues but
Figure 4. ENO1 vaccination decreased MDSC and FoxP3 cells. (A,
eft panel) Whole blood from untreated (white bars), empty-vaccinated
gray bars), and ENO1-vaccinated (black bars) mice was stained after
ed blood cell lysis with anti-CD11b and anti-GR1 mAbs and directly
cquired with a FACSCalibur. The percentage of double-positive cells
rom individual mice is reported as mean  SEM; n  4–8 per group.
Right panel) The presence of FoxP3 transcriptional factor was assessed
n peripheral blood mononuclear cells from untreated (white bars), emp-
y-vaccinated (gray bars), and ENO1-vaccinated (black bars) mice. The
ercentage of positive cells between total CD4/CD25 cells evaluated
n each single mouse is reported as mean  SEM; n  4–8 per group.
B) Quantification of FoxP3 cells in transformed pancreatic ducts (n 5
or each group). (C–F) Pancreases from empty- and ENO1-vaccinated
ice killed at (C and D) 24 and (E and F) 36 weeks of age, respectively,
ere stained with the anti-FoxP3 antibody. **P  .01, ***P  .0001
alues significantly different from untreated mice and §P  .01, §§P 
001 values significantly different from empty-vaccinated mice.
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1104 CAPPELLO ET AL GASTROENTEROLOGY Vol. 144, No. 5never for as long as in our study. We show that ENO1
NA vaccination significantly prolongs survival from 336
o 474 days of age, the longest overall survival ever re-
orted.
In this study, we showed that ENO1-vaccinated mice
displayed a higher amount of serum anti-ENO1 IgG and,
notably, that they were able to bind the cell surface of
murine PDA cells and induce their killing by complement-
dependent cytotoxicity, which has been proposed as an
effector mechanism of antitumor immunity.17,18 Induc-
tion of anti-ENO1 antibody correlates with the increase of
Figure 5. ENO1 vaccination increased IL-17 production. Spleen cells
from untreated (white bars), empty-vaccinated (gray bars), and ENO1-
vaccinated (black bars) mice were stimulated with PMA and ionomycin
overnight in the presence of brefeldin A (A) ex vivo and (B) after in vitro
stimulation with rENO1 for 7 days and then stained for intracellular cy-
tokines. The percentage of positive cells in total CD4 cells evaluated in
each single mouse is represented as mean  SEM; n  6 per group.
*P  .05 values significantly different from untreated mice and §P  .05
values significantly different from empty-vaccinated mice. (C) Quantifica-
tion of CD3 cells in transformed pancreatic ducts (n  6–8 for each
roup). (D–F) Pancreases from (D) untreated, (E) empty-vaccinated, and
F) ENO1-vaccinated mice killed at 24 weeks of age, respectively, were
tained with the anti-CD3 antibody. *P .05 values significantly different
rom untreated mice; §§P .01 values significantly different from empty-
vaccinated mice.ENO1-specific Th1 and Th17 T cells. The latter, in par-ticular, may be crucially important in helping B cells to
produce a pronounced amount of antibodies with prefer-
ential isotype class switching to IgG1, IgG2a, IgG2b, and
IgG319 and IFN- to IgG2a.20 Accordingly, we have doc-
umented a strong increase in T lymphocytes that infiltrate
the tumor area in ENO1-vaccinated mice. We are currently
investigating other anti-tumor mechanisms dependent on
anti-ENO1 IgG, especially after the important demonstra-
tion by Guo et al that, in addition to surface molecules,
proteins hidden within cells can also be attacked by anti-
bodies.21 Another possible role is the inhibition of migra-
ion of pancreatic tumor cells or MDSCs into the tumor
hrough the ENO1-plasminogen pathway blockade.22,23
An additional important effect of ENO1 vaccination is
he significant decrease of MDSCs and Treg cells. The
assive secretion of IL-6 in the pancreas of ENO1-vacci-
ated mice (data not shown) may explain the increase of
h17 rather than FoxP3 cells.24 Th17 cells recruit neu-
trophils and eosinophils,25 also present in pancreatic tu-
mor lesions from empty-vaccinated mice (data not
shown), and this native immune response partly impeded
tumor progression, particularly at the beginning; indeed,
at 24 weeks of age, both empty- and ENO1-vaccinated
mice presented a lower percentage of transformed pancre-
atic ducts compared with untreated mice. However, only
the combination of the innate and acquired immune
responses induced by ENO1 vaccination was able to sig-
nificantly delay tumor progression. At 36 weeks of age,
only ENO1-vaccinated mice showed the lower percentage
of transformed pancreatic ducts, and 2 of these 5 mice
displayed an almost entirely histologically normal pan-
creas. Nevertheless, when suppressive immune cells re-
stored percentages similar to those of the controls, pro-
gression was no longer counteracted and death ensued.
However, it is possible that repeated boosters are required,
as for other antigens, to maintain the minimal antigen
concentration necessary for adequate effector activation.
Thus, all studies aimed to limit suppressor cells by a
combination of different strategies are highly applicable,
and it is likely that a combined vaccination schedule or
different settings might be more efficient. In a genetically
engineered mice model of lung adenocarcinoma, vaccina-
tion clearly stimulated specific T cells that soon disap-
peared; tumor growth, in parallel, was slower at the be-
ginning but then became similar to that in control mice.26
This also endorses the great potential of the vaccination
even if researchers still have to work on the most effective
combination and timing. The choice of xenogenic rather
than syngeneic antigen or other kinds of vectors remains
open; many studies have shown that human TAA com-
pared with the mouse orthologue, or viral vectors com-
pared with plasmid vectors used to vaccinate tumor-bear-
ing mice, are more efficient in inducing tumor immunity
as well as autoimmunity. Thus, xenogenic TAA or viral
components aid the immune system in breaking tolerance
or ignorance against a “self”-protein.27–29 In our case, we
have previously shown that peripheral blood mononu-
clear cells from patients with PDA specifically secreted
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May 2013 DNA VACCINATION DELAYS PROGRESSION OF PDA 1105IFN- in response to the syngeneic recombinant protein,
nd here we show that mice vaccinated with the xenogenic
rotein produce antibodies against the syngeneic native
rotein.
Our results are, however, very promising. Few of the
any new strategies seem to be effective in prolonging
urvival beyond 1 year,15 while the optimal adjuvant ap-
roach after resection is still unclear.30 Together these
ndings suggest that ENO1 vaccination in patients with
resected PDA might increase the Th17 population and
limit the expansion of MDSCs, leading to an effective
immune response that tackles recurrence. In addition, this
observation endorses previous data on the effector role of
Th17 cells in tumors,31–33 even if their specific contribu-
tion in PDA remains to be clarified. DNA vaccines could
be used in pancreatic cancer as adjuvants to conventional
treatments, in the management of minimal residual dis-
ease, and as a way of increasing the overall survival of the
80% of patients with resected PDA who develop recur-
rences.
Increasing data indicate that chemoimmunotherapy
may constitute a new strategy to control tumor progres-
sion.34 The immune system, indeed, could be elicited in 2
ays by conventional therapies. Some therapeutic pro-
rams elicit specific cellular responses that render tumor
ell death immunogenic.35 Other drugs may have side
ffects that stimulate the immune system through differ-
nt mechanisms. Moreover, vaccination against cancer-
pecific antigens may sensitize a tumor to subsequent
hemotherapy,34 and in this contest the ENO1 vaccine can
also be applied to patients with chemoresistant PDA.
Lastly, the chemotherapeutic drug gemcitabine36,37 (but
not doxorubicin/cyclophosphamide38) eliminates MD-
Cs39 and cyclophosphamide eliminates Tregs,40 which
constitute one of the main immunosuppressive factors in
cancer as well as tumor-associated stromal cells, and sev-
eral strategies targeting them are currently being ex-
plored.39,41 Very promising, indeed, is the therapeutic ef-
ficacy of the ENO1 vaccine observed when the
Figure 6. Late ENO1 vaccination significantly delayed progression of PDA
stablished, every 3 weeks for a total of 3 rounds. (A) Percentage of transfor
roup). (B) Quantification of the largest focus (mm) in the pancreas of mice
alues compared with empty-vaccinated mice.dministration protocol is started at 32 to 36 weeks ofge. The right drug combination might transform our
rend in significant results. Overall, the present data in-
icate that it may be possible to design adjuvant therapies
o elicit anti-ENO1 responses in patients with resected
DA to prevent recurrence or to prolong survival of un-
reatable patients.
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